Small-molecule HDAC and Akt inhibitors suppress tumor growth and enhance immunotherapy in multiple myeloma

BACKGROUND: Multiple myeloma (MM) is an incurable disease. The acquisition of resistance to drugs, including immunomodulatory drugs (IMiDs), has a negative effect on its prognosis. Cereblon (CRBN) is a key mediator of the bioactivities of IMiDs such as lenalidomide. Moreover, genetic alteration of C...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:J Exp Clin Cancer Res
Glavni autori: Hirano, Mitsuhito, Imai, Yoichi, Kaito, Yuta, Murayama, Takahiko, Sato, Kota, Ishida, Tadao, Yamamoto, Junichi, Ito, Takumi, Futami, Muneyoshi, Ri, Masaki, Yasui, Hiroshi, Denda, Tamami, Tanaka, Yukihisa, Ota, Yasunori, Nojima, Masanori, Kamikubo, Yasuhiko, Gotoh, Noriko, Iida, Shinsuke, Handa, Hiroshi, Tojo, Arinobu
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2021
Teme:
Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7989023/
https://ncbi.nlm.nih.gov/pubmed/33757580
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13046-021-01909-7
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items